Old Mutual Global Investors UK Ltd. trimmed its stake in Cigna Corporation (NYSE:CI) by 53.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 224,353 shares of the health services provider’s stock after selling 260,553 shares during the period. Old Mutual Global Investors UK Ltd. owned about 0.09% of Cigna Corporation worth $41,940,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Saratoga Research & Investment Management bought a new stake in Cigna Corporation in the third quarter valued at $112,000. Capstone Investment Advisors Netherlands B.V. bought a new stake in shares of Cigna Corporation during the second quarter worth $106,000. American Beacon Advisors Inc. bought a new stake in shares of Cigna Corporation during the first quarter worth $102,000. Parallel Advisors LLC grew its holdings in shares of Cigna Corporation by 62.3% during the second quarter. Parallel Advisors LLC now owns 800 shares of the health services provider’s stock worth $139,000 after purchasing an additional 307 shares during the last quarter. Finally, Acrospire Investment Management LLC grew its holdings in shares of Cigna Corporation by 66.7% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the health services provider’s stock worth $167,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 88.16% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/old-mutual-global-investors-uk-ltd-has-41-94-million-holdings-in-cigna-corporation-ci/1685493.html.

Cigna Corporation (NYSE:CI) traded down $0.08 during mid-day trading on Tuesday, reaching $204.92. The company’s stock had a trading volume of 16,190 shares, compared to its average volume of 1,400,000. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.39 and a current ratio of 0.39. The company has a market capitalization of $50,540.00, a P/E ratio of 19.45, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. Cigna Corporation has a 12-month low of $122.35 and a 12-month high of $205.75.

Cigna Corporation (NYSE:CI) last posted its quarterly earnings results on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.36 by $0.47. The firm had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.17 billion. Cigna Corporation had a return on equity of 18.85% and a net margin of 5.74%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same period last year, the company earned $1.94 earnings per share. equities analysts forecast that Cigna Corporation will post 10.39 EPS for the current fiscal year.

In related news, VP Mary T. Hoeltzel sold 525 shares of Cigna Corporation stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $177.59, for a total transaction of $93,234.75. Following the completion of the sale, the vice president now directly owns 1,924 shares of the company’s stock, valued at approximately $341,683.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Lisa R. Bacus sold 2,236 shares of Cigna Corporation stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $179.95, for a total value of $402,368.20. Following the sale, the executive vice president now directly owns 18,501 shares of the company’s stock, valued at $3,329,254.95. The disclosure for this sale can be found here. Insiders have sold a total of 4,240 shares of company stock valued at $772,032 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Several equities analysts recently issued reports on CI shares. Morgan Stanley raised their price target on Cigna Corporation from $184.00 to $188.00 and gave the company an “overweight” rating in a report on Monday, August 7th. Deutsche Bank AG raised their price target on Cigna Corporation from $180.00 to $190.00 and gave the company a “buy” rating in a report on Monday, August 7th. BidaskClub upgraded Cigna Corporation from a “buy” rating to a “strong-buy” rating in a report on Friday, August 18th. Jefferies Group LLC raised their price target on Cigna Corporation from $221.00 to $231.00 and gave the company a “buy” rating in a report on Friday. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $196.00 price target on shares of Cigna Corporation in a report on Friday, August 4th. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $201.50.

About Cigna Corporation

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corporation (NYSE:CI).

Institutional Ownership by Quarter for Cigna Corporation (NYSE:CI)

Receive News & Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.